Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.3% – What’s Next?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s share price was up 3.3% during mid-day trading on Thursday . The company traded as high as $1.28 and last traded at $1.27. Approximately 34,484 shares were traded during trading, a decline of 60% from the average daily volume of 86,109 shares. The stock had previously closed at $1.23.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TELO shares. Zacks Research upgraded shares of Telomir Pharmaceuticals to a “hold” rating in a report on Wednesday, March 18th. Wall Street Zen raised shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Price Performance

The firm has a 50 day moving average of $1.31 and a two-hundred day moving average of $1.31. The stock has a market cap of $83.22 million, a PE ratio of -4.17 and a beta of -0.24.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its earnings results on Thursday, May 14th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04.

Institutional Trading of Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the period. Marshall Wace LLP acquired a new position in Telomir Pharmaceuticals in the second quarter valued at $95,000. Raymond James Financial Inc. raised its stake in shares of Telomir Pharmaceuticals by 4,101.9% during the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after purchasing an additional 73,547 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals during the second quarter worth approximately $62,000. Finally, XTX Topco Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the fourth quarter worth approximately $53,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.